Effect of roflumilast and inhaledcorticosteroid/long-acting b2-agonist on chronic obstructive pulmonary disease exacerbations (RE2SPOND): A randomized clinical trial Academic Article uri icon

Overview

MeSH Major

  • Adrenal Cortex Hormones
  • Adrenergic beta-2 Receptor Agonists
  • Aminopyridines
  • Benzamides
  • Bronchitis, Chronic
  • Muscarinic Antagonists
  • Pulmonary Disease, Chronic Obstructive

abstract

  • Roflumilast failed to statistically significantly reduce moderate and/or severe exacerbations in the overall population. Roflumilast improved lung function and reduced exacerbations in participants with frequent exacerbations and/or hospitalization history. The safety profile of roflumilast was consistent with that of previous studies. Clinical trial registered with www.clinicaltrials.gov (NCT01443845).

publication date

  • September 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1164/rccm.201607-1349OC

PubMed ID

  • 27585384

Additional Document Info

start page

  • 559

end page

  • 67

volume

  • 194

number

  • 5